1 emia due to pituitary corticotroph adenomas (Cushing disease).

2 tary adenomas in 80% of patients with proven Cushing disease.

3 rbances mimicking hypercortisolism caused by Cushing disease.

4 ctive pituitary targeted pharmacotherapy for Cushing disease.

5 gnaling may be a novel strategy for treating Cushing disease.

6  EGFR might provide a therapeutic target for Cushing disease.

7  but the long-term survival of patients with Cushing disease after transsphenoidal surgery has not be

8 en; mean age, 38 years) who were treated for Cushing disease between 1978 and 1996.

9                                              Cushing disease caused by adrenocorticotropin (ACTH)-sec

10                                              Cushing disease (CD) is a life-threatening disorder attr

11 pling of the petrosal sinuses to distinguish Cushing disease from the ectopic adrenocorticotropic hor

12 ntral to peripheral ACTH were diagnostic for Cushing disease (> 2 before administration of CRH and >

13                                    Untreated Cushing disease historically has a high mortality rate,

14                     The primary treatment of Cushing disease (hypercortisolism due to ACTH-producing

15 ell as a handful of other cases of infantile Cushing disease in the literature, suggests that feature

16                                              Cushing disease is a condition in which the pituitary gl

17                                              Cushing disease is exceedingly rare in children, especia

18 ors in 43 patients (20 pheochromocytomas, 13 Cushing disease or syndrome, and 10 others), nonfunction

19 rom 16 of 20 patients with surgically proven Cushing disease (sensitivity, 80% [95% CI, 56% to 96%]).

20 rom 19 of 20 patients with surgically proven Cushing disease (sensitivity, 95% [CI, 75% to 99%]).

21             Survival of patients treated for Cushing disease with current management techniques betwe